4d Molecular Therapeutics, INC. (FDMT) — SEC Filings

Overview

4d Molecular Therapeutics, INC. (FDMT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 10, 2025: On December 10, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but provides no further specific details regarding the nature of these events, any associated parties, or financial implications within the provided text.

Sentiment Summary

Across 47 filings, the sentiment breakdown is: 1 bearish, 46 neutral. The dominant filing sentiment for 4d Molecular Therapeutics, INC. is neutral.

Filing Type Overview

4d Molecular Therapeutics, INC. (FDMT) has filed 20 8-K, 5 10-Q, 2 DEF 14A, 17 SC 13G/A, 2 SC 13G, 1 10-K with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (47)

• 4D Molecular Therapeutics Files 8-K — 8-K · Dec 10, 2025 Risk: medium
  On December 10, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, but provides no further specific details
• 4D Molecular Therapeutics Files 8-K on Board and Compensation Changes — 8-K · Nov 17, 2025 Risk: low
  On November 17, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing ind
• 4D Molecular Therapeutics Files 8-K on Financials — 8-K · Nov 10, 2025 Risk: low
  On November 10, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing pertains to the company's results of operations and financial condition, a
• 8-K Filing — 8-K · Nov 7, 2025
• 4D Molecular Therapeutics Files 8-K — 8-K · Nov 6, 2025 Risk: low
  On November 6, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates information related to the company's results of operations and fi
• 4D Molecular Therapeutics Files 8-K — 8-K · Oct 31, 2025 Risk: medium
  On October 31, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement. Specific details o
• 4D Molecular Therapeutics Files 8-K with Board and Compensation Updates — 8-K · Oct 2, 2025 Risk: low
  On September 30, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements.
• 4D Molecular Therapeutics' Losses Widen Amid R&D Surge — 10-Q · Aug 11, 2025 Risk: high
  4D Molecular Therapeutics, Inc. reported a net loss of $62.1 million for the three months ended June 30, 2025, an increase from a net loss of $50.3 million for
• 4D Molecular Therapeutics Files 8-K on Governance Changes — 8-K · Jul 2, 2025 Risk: low
  On June 27, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The f
• 4D Molecular Therapeutics Holds Annual Stockholder Meeting — 8-K · Jun 20, 2025 Risk: low
  On June 17, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders. The company's stockholders
• 4D Molecular Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  4D Molecular Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations,
• 4D Molecular Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  4D Molecular Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting on June 17, 2025. The filing outlines t
• 4D Molecular Therapeutics Files 8-K — 8-K · Feb 28, 2025 Risk: low
  On February 28, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condi
• 4D Molecular Therapeutics Files 8-K — 8-K · Feb 10, 2025 Risk: low
  On February 8, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of information. The company is
• 4D Molecular Therapeutics Files 8-K — 8-K · Jan 10, 2025 Risk: low
  On January 10, 2025, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates the company is involved in the biological products sector, specif
• 4D Molecular Therapeutics Reports Unregistered Equity Sale — 8-K · Dec 11, 2024 Risk: medium
  On December 6, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report detailing the unregistered sale of equity securities. The filing does not specify the n
• SC 13G/A Filing — SC 13G/A · Dec 6, 2024
• SC 13G/A Filing — SC 13G/A · Nov 15, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• 4D Molecular Therapeutics Q3 Update — 10-Q · Nov 13, 2024 Risk: medium
  4D Molecular Therapeutics, Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial filings indicate activities
• SC 13G/A Filing — SC 13G/A · Nov 13, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• SC 13G Filing — SC 13G · Nov 6, 2024
• SC 13G Filing — SC 13G · Nov 4, 2024
• SC 13G/A Filing — SC 13G/A · Oct 21, 2024
• 4D Molecular Therapeutics Files 8-K Report — 8-K · Sep 18, 2024 Risk: medium
  On September 18, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Event' without specifying further details in the prov
• 4D Molecular Therapeutics Q2 2024 Update — 10-Q · Aug 8, 2024 Risk: medium
  4D Molecular Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial activities, including its public offer
• 4D Molecular Therapeutics Files 8-K — 8-K · Jul 23, 2024 Risk: medium
  On July 23, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning the company is releasing materia
• 4D Molecular Therapeutics Files 8-K Report — 8-K · Jul 17, 2024 Risk: low
  On July 17, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under 'Other Events'. No s
• 4D Molecular Therapeutics Files 8-K — 8-K · Jun 7, 2024 Risk: medium
  On June 7, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also inc
• 4D Molecular Therapeutics Holds Annual Stockholder Meeting — 8-K · May 24, 2024 Risk: low
  On May 21, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report indicating that it held its Annual Meeting of Stockholders. The primary purpose of the meet
• 4D Molecular Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  4D Molecular Therapeutics, Inc. (FDMT) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. 4D Molecular Therapeutics, Inc. filed a 10-Q report for the
• 4D Molecular Therapeutics Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 10, 2024 Risk: low
  4D Molecular Therapeutics, Inc. (FDMT) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. The 2024 Annual Meeting of Stockholders for 4D Molecula
• 4D Molecular Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
  4D Molecular Therapeutics, Inc. (FDMT) filed a Annual Report (10-K) with the SEC on February 29, 2024. 4D Molecular Therapeutics, Inc. filed its 2023 Form 10-K
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• 4D Molecular Therapeutics Files Routine 8-K on Feb 6 Event — 8-K · Feb 9, 2024 Risk: low
  4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K on February 9, 2024, reporting an event that occurred on February 6, 2024. This filing is a routine update,
• BlackRock Amends 4D Molecular Therapeutics Stake to 7.0% — SC 13G/A · Jan 25, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership in 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT). As of December 31, 202
• Viking Global Amends 4DMT Stake, Signals Continued Interest — SC 13G/A · Jan 8, 2024
  Viking Global Investors LP, a major investment firm, filed an amended SC 13G/A on January 8, 2024, indicating a change in their beneficial ownership of 4D Molec
• 4D Molecular Therapeutics Reports Officer/Director Changes, Comp. Arrangements — 8-K · Jan 4, 2024
  4D Molecular Therapeutics, Inc. filed an 8-K on January 4, 2024, reporting an event that occurred on January 1, 2024, related to changes in directors or officer

Risk Profile

Risk Assessment: Of FDMT's 26 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from 4d Molecular Therapeutics, INC.'s most recent 10-Q filing (Aug 11, 2025):

• Revenue: $0.5M
• Net Income: -$62.1M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: N/A
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Jacob Chacko

Industry Context

The gene therapy sector is characterized by high R&D intensity, significant capital requirements, and long development timelines. Companies like 4D Molecular Therapeutics operate in a competitive landscape with a focus on addressing unmet medical needs through innovative treatments. Regulatory pathways are complex, and clinical success is paramount for value creation.

Top Tags

8-k (5) · corporate-governance (5) · biotech (5) · 8-K (4) · 10-Q (4) · regulatory-filing (4) · executive-compensation (3) · SEC Filing (3) · Biotechnology (3) · other-events (2)

Key Numbers

• Net Loss (Q2 2025): $62.1M — Increased from $50.3M in Q2 2024, indicating widening losses.
• Net Loss (Six Months Ended June 30, 2025): $120.9M — Increased from $98.1M in the prior year period.
• Collaboration and License Revenue (Q2 2025): $0.5M — Decreased from $1.5M in Q2 2024, primarily from Cystic Fibrosis Foundation agreement.
• Research and Development Expense (Q2 2025): $53.9M — Increased from $44.0M in Q2 2024, driven by clinical trial activities.
• Workforce Reduction Charge (Q2 2025): $2.0M — Included in R&D expenses, reflecting cost-cutting efforts.
• Net Proceeds from Follow-on Public Offering: $200.0M — Raised in February 2024, providing capital for operations.
• At-The-Market Offering Program Limit: $150.0M — Potential future capital source through Jefferies LLC.
• SEC File Number: 001-39782 — Identifies the company's filing with the SEC.
• IRS Employer Identification No.: 47-3506994 — Company's tax identification number.
• Reporting Period: Q1 2025 — The first quarter of 2025 financial and operational data is presented.
• End of Fiscal Period: 2025-03-31 — The date as of which the financial statements are reported.
• Filing Date: 2025-05-08 — The date the 10-Q was officially submitted to the SEC.
• Commission File Number: 001-39782 — Identifies the company's SEC filing history.
• Reporting Period End Date: 2024-09-30 — Indicates the end of the fiscal quarter for which financial information is reported.
• Q3 2024 Start Date: 2024-07-01 — Marks the beginning of the third fiscal quarter of 2024.

Related Companies

4DMT

Frequently Asked Questions